Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer
- 1 June 1995
- Vol. 117 (6) , 601-608
- https://doi.org/10.1016/s0039-6060(95)80001-8
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Sapporo Bioscience Foundation
This publication has 25 references indexed in Scilit:
- Specific Stimulation by Estradiol of Tissue-Type Plasminogen Activator Production in 7,12-Dimethylbenz[a]Anthracene-Induced Rat Mammary Tumor CellsHormone and Metabolic Research, 1992
- Why do so many prognostic factors fail to pan out?Breast Cancer Research and Treatment, 1992
- Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines.Journal of Clinical Investigation, 1991
- Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: Correlation with clinical outcome of anti‐estrogen therapyInternational Journal of Cancer, 1991
- Indicators of Prognosis in Node-Negative Breast CancerNew England Journal of Medicine, 1990
- Cathepsin D and Prognosis in Breast CancerNew England Journal of Medicine, 1990
- Presence of immunoreactive endothelin in human plasmaFEBS Letters, 1989
- Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast CancerNew England Journal of Medicine, 1989
- Meeting Highlights: Adjuvant Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958